ライフサイエンスコーパス: coagulopathy

1 fficiency, acute cardiovascular failure, and coagulopathy.

2 road spectrum of cardiovascular diseases and coagulopathy.

3 egrees C), acidosis (median pH <7.2), and/or coagulopathy.

4 ying myosin might contribute to acute trauma coagulopathy.

5 d should not be used exclusively to evaluate coagulopathy.

6 that Gas6 may be involved in cancer-induced coagulopathy.

7 l management of patients with trauma-induced coagulopathy.

8 both patients had evidence of a consumptive coagulopathy.

9 ratio-based definitions for acute traumatic coagulopathy.

10 l and esthetic impairment, and intravascular coagulopathy.

11 a role for cryoprecipitate in reversing rtPA coagulopathy.

12 tant severe pathology (liver and spleen) and coagulopathy.

13 h a 66% lower risk of clinically significant coagulopathy.

14 apid and reliable method to assess traumatic coagulopathy.

15 reased risk of bleeding due to a consumption coagulopathy.

16 garding fluid resuscitation and treatment of coagulopathy.

17 a high mortality and is increased in case of coagulopathy.

18 and improve thrombin generation in acquired coagulopathy.

19 ested that ANXII plays a pivotal role in APL coagulopathy.

20 orrhagic shock treatment for acute traumatic coagulopathy.

21 hout coagulopathy and 0.23% among those with coagulopathy.

22 ransgenic mice, worsening their survival and coagulopathy.

23 infection, vasculopathy, cardioembolism, and coagulopathy.

24 s dysregulate hemostatic pathways, prompting coagulopathy.

25 must occur before laboratory confirmation of coagulopathy.

26 sed for markers of leukocyte trafficking and coagulopathy.

27 esistance, impaired drug clearance, and mild coagulopathy.

28 tical factor that acts by inducing placental coagulopathy.

29 votal role in haemostasis and trauma-induced coagulopathy.

30 ere CD4(+) and CD8(+) T-cell lymphopenia and coagulopathy.

31 othelial damage, prolonged stays in bed, and coagulopathy.

32 inflammation, thrombotic complications, and coagulopathy.

33 1 patients (0.23%; 95% CI, 0.15%-0.34%) with coagulopathy.

34 D-19 acute respiratory distress syndrome and coagulopathy.

35 dothelial cell injury in COVID-19-associated coagulopathy.

36 ggests an important role of COVID-19-induced coagulopathy.

37 function may lead to thrombosis and systemic coagulopathy.

38 taneous thrombosis, hemorrhages and systemic coagulopathy.

39 e prevention and treatment of trauma-induced coagulopathy.

40 a (APL) is commonly complicated by a complex coagulopathy.

41 p = 0.32) in patients with sepsis-associated coagulopathy.

42 instability, capillary leak, and consumptive coagulopathy.

43 ections are frequently complicated by severe coagulopathies.

44 eceive anticoagulation therapy or experience coagulopathies.

45 g platelet reductions typical of consumptive coagulopathies.

46 The most prevalent comorbidities were coagulopathy (36.0%), fluid and electrolyte disorders (3

47 Acute traumatic coagulopathy affected 50% of subjects if defined as an i

48 Dilutional coagulopathy after resuscitation with crystalloids/collo

49 m identified bowel gangrene and peritonitis, coagulopathy, age, the use of stoma, and chronic kidney

50 trigger immune activation, inflammation, and coagulopathy, all of which are key factors that drive HI

51 llowing a rapid and timely identification of coagulopathy along with enabling an individualized, goal

52 nsights into the pathogenesis of RVV-induced coagulopathies and indicate that DrKIn-I is a novel APC

53 ar puncture was 0.20% among patients without coagulopathy and 0.23% among those with coagulopathy.

54 Pros1-/- mice die in utero,from a fulminant coagulopathy and associated hemorrhages.

55 peutic strategy to prevent infection-induced coagulopathy and associated tissue damage.

56 Coagulopathy and bleeding after severe injury is a commo

57 l injury markers (HMGB1, histones) confirmed coagulopathy and cell injury.

58 in the form of microparticles contribute to coagulopathy and further organ dysfunction.

59 ary outcome was drug-induced ALF (defined as coagulopathy and hepatic encephalopathy without underlyi

60 To define the relationship between coagulopathy and hepatocellular tropism, we compared inf

61 Massive hemorrhage is associated with coagulopathy and high mortality.

62 ere administered after each session to avoid coagulopathy and hypogammaglobulinemia.

63 tracorporeal membrane oxygenation-associated coagulopathy and identify options to optimize its monito

64 cations of perioperative hypothermia include coagulopathy and increased transfusion requirement, surg

65 llows for rapid and timely identification of coagulopathy and individualized, goal-directed transfusi

66 agement of patients with warfarin-associated coagulopathy and intracerebral hemorrhage.

67 Whether this early coagulopathy and later propensity to infection, multiple

68 point-of-care device to detect the onset of coagulopathy and monitor response following therapeutic

69 allows 'point-of-care' testing of postinjury coagulopathy and monitoring of transfusion strategies.

70 on: In patients with advanced cirrhosis with coagulopathy and nonvariceal upper GI bleeding, TEG-guid

71 ment with RA101295 also improved consumptive coagulopathy and preserved endothelial anticoagulant and

72 of viral hemorrhagic disease and associated coagulopathy and suggest directions for clinical managem

73 t changes and advancement of early traumatic coagulopathy and the important role of substantial bleed

74 clinical hallmarks of EHF, including severe coagulopathy and uncontrolled host immune responses.

75 e showed signs of disseminated intravascular coagulopathy and were lost because of proteinuria or inf

76 fibrinogen replacement therapy for acquired coagulopathies, and additional studies are underway.

77 es bowel rest, correction of cytopathies and coagulopathies, and broad spectrum antibiotics and antif

78 tory response, and endothelial dysfunction), coagulopathy, and angiogenesis with the severity of live

79 ory host responses, severe thrombocytopenia, coagulopathy, and death.

80 ete spectrum of HLH, including splenomegaly, coagulopathy, and decreased NK cell cytotoxicity, indica

81 els of hepatic fibrin, decreased evidence of coagulopathy, and diminished cytokine production (interl

82 o" of RBC:FFP leads to earlier correction of coagulopathy, and earlier and prolonged repletion of som

83 ypothermia and acidosis, direct treatment of coagulopathy, and early transfusion in trauma patients.

84 ur), and is associated with MT requirements, coagulopathy, and hemorrhage-related death.

85 with leaky capillary syndrome, disseminated coagulopathy, and high mortality with limited treatment

86 issue perfusion and for preventing acidosis, coagulopathy, and hypothermia, referred to as the 'letha

87 h the anti-NS1-DR4 Ig led to plasma leakage, coagulopathy, and morality in mice with warfarinized ant

88 ly infected with P. coatneyi develop anemia, coagulopathy, and renal and metabolic dysfunction.

89 ent sepsis-induced inflammation, consumptive coagulopathy, and subsequent organ failure and death.

90 use deformity, pain, and local intravascular coagulopathy, and they expand with time.

91 early in severe shock, leading to postinjury coagulopathy, and ultimately hemorrhage-related death.

92 in multiple ways to endothelial activation, coagulopathy, and vascular leakage in sepsis.

93 ic syndrome resulting from thrombocytopenia, coagulopathy, and vasculopathy.

94 Since coagulopathies are a hallmark of T2D, we wondered whethe

95 These data imply that coagulopathies are an important feature of T2D, and may

96 We conclude that whereas coagulopathies are more exacerbated in LPS-treated TF(-/

97 D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data d

98 Conventional concepts of traumatic coagulopathy as a late occurring condition in response t

99 tial hepatocyte infection, liver damage, and coagulopathy as defined by virological, clinical, and pa

100 gulation inhibitor activity triggered severe coagulopathy as indicated by prolonged coagulation times

101 ads to increased clot firmness in dilutional coagulopathy as measured with thromboelastometry.

102 sting aids anesthesiologists in diagnosis of coagulopathy as well as therapeutic optimization of anti

103 s in patients with cirrhosis and significant coagulopathy (as defined by routine coagulation tests) a

104 uce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial:

105 lities that mimic disseminated intravascular coagulopathy associated with sepsis, with the major diff

106 ocytes likely contributes to the consumptive coagulopathy associated with severe YF in primates and h

107 near-normal prothrombin time can reverse the coagulopathy associated with superwarfarins.

108 omboelastometry can identify acute traumatic coagulopathy at 5 mins and predict the need for massive

109 Coagulopathy at the time of lumbar puncture.

110 ology and pathophysiology of acute traumatic coagulopathy (ATC).

111 In patients with cirrhosis and significant coagulopathy before invasive procedures, TEG-guided tran

112 d not routinely correct thrombocytopenia and coagulopathy before low-risk therapeutic paracentesis, t

113 is is a central component of acute traumatic coagulopathy but a group of patients present with low le

114 We are moving toward avoiding coagulopathy by individualized, goal-directed transfusio

115 lopathy, in subgroup analyses of severity of coagulopathy by pediatric specialty or medical indicatio

116 Thus, in 2005, a strategy aiming at avoiding coagulopathy by proactive resuscitation with blood produ

117 Defining acute traumatic coagulopathy by using an international normalized ratio

118 -grained resolution into COVID-19 associated coagulopathy (CAC) and set the stage for personalizing t

119 ood pressure control, reversal of associated coagulopathy, care in a dedicated stroke unit, and ident

120 n, a potentially interfering molecule in the coagulopathy cascade.

121 Recent multistate outbreaks of coagulopathy caused by brodifacoum-tainted synthetic can

122 avirus 2 pathogenesis is COVID-19-associated coagulopathy, characterised by increased thrombotic and

123 vation of the PC which was associated with a coagulopathy characterized by inactivation of the coagul

124 al membrane oxygenation is associated with a coagulopathy characterized by thromboembolic and hemorrh

125 egulated hemostasis, including a consumptive coagulopathy, characterized by compensatory increase in

126 nown, it is clear that hyperinflammation and coagulopathy contribute to disease severity.

127 ecause of the perception that the coexistent coagulopathy could promote bleeding.

128 Early identification of shock and coagulopathy coupled with damage control resuscitation a

129 elial dysfunction (sVCAM-1 and sICAM-1), and coagulopathy (D-dimer) were related to higher CTP values

130 isease, hypothyroidism, liver disease, AIDS, coagulopathy, deficiency anemia, obesity, alcohol abuse,

131 Acute traumatic coagulopathy defined as an international normalized rati

132 t for potential confounders, acute traumatic coagulopathy defined as an international normalized rati

133 ime ratio was calculated and acute traumatic coagulopathy defined as laboratory prothrombin time rati

134 n in patients with cirrhosis and significant coagulopathy (defined in this study as INR >1.8 and/or p

135 A total of 96 patients with significant coagulopathy (defined in this study as INR >1.8 and/or P

136 r understanding of the process by which this coagulopathy develops and how it may be inhibited.

137 Our understanding of perioperative coagulopathy, diagnostic tools, and therapeutic approach

138 lism, and rarely, disseminated intravascular coagulopathy (DIC), with patients generally not displayi

139 in patients with disseminated intravascular coagulopathy (DIC).

140 tracorporeal membrane oxygenation-associated coagulopathy differ between venovenous extracorporeal me

141 treatments may not be sufficient to reverse coagulopathy early enough to prevent hematoma expansion

142 n of findings, including hyperbilirubinemia, coagulopathy, encephalopathy, and ascites formation.

143 )-induced infection can be associated with a coagulopathy, findings consistent with infection-induced

144 nt acidosis, hypothermia and the progressive coagulopathy following injury, trauma victims the world

145 on recent literature regarding treatment of coagulopathy for patients with life-threatening bleeding

146 ach for fluid resuscitation and treatment of coagulopathy for trauma patients.

147 Coagulopathy has a significant impact on survival after

148 Our understanding of hemostasis and coagulopathy has improved, leading to a change in the pr

149 derstanding of the hemostatic process and of coagulopathy has improved.

150 res of NPSLE, in particular those related to coagulopathy, have been characterized and an evidence-ba

151 An understanding of the coagulopathy, hemostatic considerations, and therapeutic

152 d lead to stunted growth, liver dysfunction, coagulopathy, hypoglycemia, and intestinal abnormalities

153 s of fibrin and display evidence of systemic coagulopathy (i.e., thrombocytopenia, fibrinogen depleti

154 o have neurological symptoms associated with coagulopathies, immune dysfunction with or without infec

155 mboelastography, demonstrated development of coagulopathies in LPS-treated mice, which were more seve

156 implicated in the development of consumptive coagulopathies in severely envenomed patients.

157 This study defines evolution of coagulopathy in 10 pigs with acetaminophen (APAP)-induce

158 PURPOSE OF REVIEW: Coagulopathy in an ICU setting is multifactorial, but ne

159 Marked inflammation and coagulopathy in blood and tissues were prominent feature

160 on algorithm would improve the management of coagulopathy in cardiac surgery and thereby reduce blood

161 to best diagnose and manage acute traumatic coagulopathy in children.

162 diagnosis, and management of acute traumatic coagulopathy in children.

163 All anticoagulation agents may contribute to coagulopathy in critically ill patients.

164 yellow fever virus (YFV) infection, and the coagulopathy in severe YF has long been attributed to ma

165 onsidered in the prevention and treatment of coagulopathy in surgical patients.

166 increasing recognition of the importance of coagulopathy in the evolution of this disease.

167 iated depletion of platelets fully abrogated coagulopathy in the head and liver fibrin deposition.

168 tor reduced the clinical features of VT, the coagulopathy in the head, and fibrin deposition in the l

169 n therapy, need to be considered in managing coagulopathy in the ICU setting.

170 ine) and Mg on hypotensive resuscitation and coagulopathy in the rat model of severe hemorrhagic shoc

171 iopathy in the graft or systemic consumptive coagulopathy in the recipient.

172 on complicated by disseminated intravascular coagulopathy in the teriflunomide 14 mg group).

173 s incompatible with prompt correction of the coagulopathy in the trauma setting.

174 responsible for persistent ICH and post-TBI coagulopathy in this model and offer a novel approach to

175 r VII (rFVIIa) as an adjunct for reversal of coagulopathy in trauma patients, and numerous other publ

176 gnificantly according to overall severity of coagulopathy, in subgroup analyses of severity of coagul

177 evelopment of this drug in sepsis-associated coagulopathy including disseminated intravascular coagul

178 examines the current approach to postinjury coagulopathy, including identification of patients at ri

179 FE event and use of interventions to correct coagulopathy, including the administration of an adequat

180 nked to the development of sequelae, such as coagulopathy, infection, morbid myocardial events, and d

181 ed bleeding is often ascribed to consumptive coagulopathy initiated by exposed brain tissue factor.

182 lure (ALF), characterized by sudden onset of coagulopathy (international normalized ratio [INR] >= 1.

183 ytopenia (platelet count < 150x10(3)/mm(3)), coagulopathy (International Normalized Ratio>2.0), and r

184 Traumatic coagulopathy is a complex process that leads to global d

185 Although coagulopathy is a defining feature of severe YF in human

186 tracorporeal membrane oxygenation-associated coagulopathy is a multifactorial and quickly developing

187 orrhage in patients with warfarin-associated coagulopathy is an increasingly common life-threatening

188 Acute traumatic coagulopathy is associated with adverse outcomes includi

189 he emergency department, and the presence of coagulopathy is associated with increased morbidity and

190 Trauma-induced coagulopathy is common and portends poor outcomes in sev

191 We have previously reported that this coagulopathy is due to the association of severe injury

192 Acute traumatic coagulopathy is functionally characterized by a reductio

193 cornerstone of supportive treatment of this coagulopathy is management of the underlying condition.

194 ulin treatment response in sepsis-associated coagulopathy is warranted to evaluate clinical relevance

195 able intra-arterial hemostasis regardless of coagulopathy, is developed.

196 Lack of PS in mice causes lethal coagulopathy, ischemic/thrombotic injuries, vascular dys

197 rmia did not further aggravate shock-related coagulopathy, it caused a transitory attenuation of kidn

198 emangioendothelioma finds that an associated coagulopathy (Kasabach-Merritt phenomenon) occurs in 72%

199 ommon than IH but more often associated with coagulopathy (Kasabach-Merritt phenomenon).

200 coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and

201 Clinical pathology findings included coagulopathy, leukocytosis, and profound liver destructi

202 Higher bilirubin, coagulopathy, leukocytosis, and thrombocytopenia were in

203 loendothelial organs, immunostimulation, and coagulopathies, limit their application as therapeutics.

204 ve heart failure, chronic pulmonary disease, coagulopathy, liver disease, lymphoma, fluid and electro

205 fever, splenomegaly, neurologic dysfunction, coagulopathy, liver dysfunction, cytopenias, hypertrigly

206 Patients can develop hepatitis, coagulopathy, liver failure, central nervous system invo

207 d-stage liver disease, vitamin K-independent coagulopathy, low-to-normal serum gamma-glutamyl transfe

208 ngside the role of tranexamic acid and other coagulopathy management strategies.

209 Coagulopathy may deter physicians from performing a lumb

210 ); patient factors (hemodynamic instability, coagulopathy, multi-organ failure, surgical history); ri

211 es mellitus, chronic kidney disease, anemia, coagulopathy, obesity, major bleeding, acute myocardial

212 ation of these findings implicates the mixed coagulopathy observed in cirrhosis.

213 inical or laboratory features of consumptive coagulopathy occurred in 7 of 12 baboons.

214 Acute traumatic coagulopathy occurs early in hemorrhagic trauma and is a

215 Coagulopathy occurs frequently in critically ill patient

216 Coagulopathy occurs in ICU patients because of multiple

217 Acute traumatic coagulopathy occurs in the presence of tissue hypoperfus

218 5% confidence interval, 2.25-5.36; P<0.001), coagulopathy (odds ratio, 2.19; 95% confidence interval,

219 The initial coagulopathy of COVID-19 presents with prominent elevati

220 Data describing the coagulopathy of Crimean-Congo haemorrhagic fever are sca

221 Coagulopathy of Crimean-Congo haemorrhagic fever is rela

222 sence of hyperfibrinolysis suggests that the coagulopathy of Crimean-Congo haemorrhagic fever relates

223 usion protocols standardize treatment of the coagulopathy of massive bleeding, leading to rapid resto

224 in the bloodstream and mitigates the lethal coagulopathy of sepsis.

225 c fever to increase our understanding of the coagulopathy of this infectious disease.

226 d our obligation to recognize and manage the coagulopathy of trauma better than in past years.

227 and a defined mechanistic link to the "Acute Coagulopathy of Trauma" is controversial.

228 udes imbalanced inflammatory response, acute coagulopathy of trauma, and endovascular glycocalyx degr

229 n the early recognition and treatment of the coagulopathy of trauma, as well as ongoing work to defin

230 administered from the outset to prevent the coagulopathy of trauma.

231 hat demonstrates the utility of managing the coagulopathy of trauma.

232 icance of recognizing the main influences in coagulopathy of trauma.

233 ns must anticipate, recognize and manage the coagulopathy of trauma.

234 care measures for those with sepsis-induced coagulopathy or DIC.

235 trategy for liver transplant recipients with coagulopathy or hemodynamic instability after allograft

236 oid arthritis (OR, 1.19; 95% CI, 1.10-1.29); coagulopathy (OR, 1.19; 95% CI, 1.08-1.32); hypertension

237 95% confidence interval [CI]: 1.58 to 2.52), coagulopathy (OR: 2.35; 95% CI: 1.88 to 2.94), and cardi

238 1, 95% CI: 1.4 to 3.2 per mg/dl creatinine), coagulopathy (OR: 3.1, 95% CI: 1.7 to 5.8 per internatio

239 as not associated with hypertriglyceridemia, coagulopathy, or essential fatty acid deficiency.

240 cerebral hemorrhage causes, anticoagulation, coagulopathy, or immediate surgery after baseline-CT.

241 uding altered clotting factor processing and coagulopathy, organ level effects such as hemorrhage, or

242 eliopathy is involved in COVID-19-associated coagulopathy pathogenesis, we assessed markers of endoth

243 but not uPA(-/-), mice developed a systemic coagulopathy post-TBI.

244 emarkably, even in patients with significant coagulopathy, postprocedure bleeding was rare, indicatin

245 alcium level may be associated with a subtle coagulopathy predisposing to increased bleeding and migh

246 colleagues advance our understanding of the coagulopathy present in acute promyelocytic leukemia (AP

247 tal role in mediating cytoprotection against coagulopathy, proinflammatory cytokines, and vascular pe

248 multiple organ dysfunction with evidence of coagulopathy (prolonged aPTT and INR, decreased platelet

249 lbuminemia (serum albumin level, 2.58 g/dL), coagulopathy (prothrombin time > 20 s compared with that

250 Progressive postinjury coagulopathy remains the fundamental rationale for damag

251 Coagulopathy represents one of the major challenges in t

252 tions include cytopenias, liver dysfunction, coagulopathy resembling disseminated intravascular coagu

253 Trauma-induced coagulopathy results from a complex interplay between sh

254 Previous studies examining acute traumatic coagulopathy's relation with mortality are limited by in

255 result of the inconsistent manifestation of coagulopathy seen in EHF.

256 ded life support, performance status, severe coagulopathy, severe hypo or hypernatremia, and grade 3-

257 tracorporeal membrane oxygenation-associated coagulopathy should be further validated in large-scale

258 COVID-19-associated coagulopathy should be managed as it would be for any cr

259 hreatening hemorrhage at risk for postinjury coagulopathy should receive component therapy in rations

260 ng abnormal haematology, blood chemistry and coagulopathy, siRNA-treated animals had milder clinical

261 pathways, blocking this pathway represents a coagulopathy-sparing, specific and novel therapy in acut

262 The presence of bowel gangrene and coagulopathy strongly predicts mortality, suggesting tha

263 rotect against histone-induced cytotoxicity, coagulopathy, systemic inflammation, and organ damage du

264 zi et al challenge the view that consumptive coagulopathy that accompanies traumatic brain injury (TB

265 The severe coagulopathy that followed combined "knockdown" of these

266 this will progress rapidly to an endogenous coagulopathy that is independently associated with worse

267 t studies have identified an acute traumatic coagulopathy that is present on admission to the hospita

268 In acute traumatic coagulopathy, the rotational thromboelastometry clot amp

269 ay premature death due to thrombosis-related coagulopathy, thereby precluding their use in gene funct

270 We highlight the distinct contributions of coagulopathy, thrombocytopathy and endotheliopathy to th

271 DCR aims at preventing coagulopathy through permissive hypotension, limiting cr

272 nd aggressive treatment of trauma-associated coagulopathy through transfusion of high plasma to packe

273 e, predefined risk factors, and treatment of coagulopathy throughout intensive care unit admission.

274 algorithms for management of trauma induced coagulopathy (TIC) during trauma hemorrhage for viscoela

275 ding, commonly referred to as trauma-induced coagulopathy (TIC), affects a quarter of all trauma pati

276 te a risk prediction tool for trauma-induced coagulopathy (TIC), to support early therapeutic decisio

277 laboratory-based evidence of trauma-induced coagulopathy (TIC), which is associated with poorer outc

278 tality, 30-day mortality, and trauma-induced coagulopathy [(TIC), admission international normalized

279 Thrombomodulin-associated coagulopathy (TM-AC) is a newly recognized dominant blee

280 ure reduction and correction of contributing coagulopathies to achieve hemostasis.

281 rgeting future therapies for acute traumatic coagulopathy to patients with an international normalize

282 With the recognition of early coagulopathy, trauma resuscitation has shifted toward li

283 eria were terminal disease, pregnancy, known coagulopathy, uncontrolled bleeding, temperature on admi

284 kers of kidney function, liver function, and coagulopathy versus vehicle-control animals.

285 atients (0.20%; 95% CI, 0.16%-0.24%) without coagulopathy vs 24 of 10 371 patients (0.23%; 95% CI, 0.

286 Coagulopathy was defined as platelets lower than 150 x 1

287 Coagulopathy was defined as r-TEG clot strength = G < 5.

288 The coagulopathy was prevented by dabigatran etexilate treat

289 tients over 14 months at risk for postinjury coagulopathy were stratified by transfusion requirements

290 wever, only macaques developed a consumptive coagulopathy whereas YFV-infected hFRG mice did not.

291 unknown mechanism, contributing to an acute coagulopathy which exacerbates bleeding and increases mo

292 ents with advanced cirrhosis and significant coagulopathy who have nonvariceal upper gastrointestinal

293 a detection rate of 77% for acute traumatic coagulopathy with a false-positive rate of 13%.

294 dysfunction, neutrophil infiltration, airway coagulopathy with cast formation, ventilation-perfusion

295 Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, eve

296 aminotransferases >200 U/L, (2) severe ALI (coagulopathy with hyperbilirubinemia), and (3) death, al

297 Coagulopathy with sepsis or other variables, such as typ

298 time ratio in patients with acute traumatic coagulopathy, with 29% false-negative results.

299 focused on early and aggressive treatment of coagulopathy, with higher ratios of plasma and platelets

300 e viable as adults and displayed less-severe coagulopathy without vascular dysgenesis.